In retrospect, 2021 was a surprising year for venture investment in the life sciences.
Despite soaring COVID-19 cases – especially towards the end of the year due to the Omicron variant – wide-ranging supply...
2021 Venture Investment Was Bullish – Will 2022 Be The Same?
The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?
